Vaccine effectiveness (VE) measures the proportional reduction in disease risk among vaccinated compared to unvaccinated populations under real-world field conditions—distinct from efficacy measured in randomized trials. VE is estimated using cohort and case-control designs and must account for vaccination coverage variations, waning immunity over time, and evolving population immunity. Time-stratified VE analysis reveals seasonal and temporal patterns. Modern efficient designs (screening method, test-negative) are increasingly used for evaluating influenza and other seasonal vaccines.
Calculate vaccine effectiveness from published cohort and case-control studies; implement test-negative design using flu surveillance data.
Vaccine effectiveness estimates are universally applicable across all populations and time periods. Efficacy measured in trials equals effectiveness in the field.
From your work on epidemiologic study designs, you know that randomized controlled trials (RCTs) are the gold standard for estimating causal effects. When a vaccine is tested in a phase III RCT — randomized assignment, blinded outcome assessment, controlled conditions — the result is vaccine efficacy (VE_trial): the proportional reduction in disease incidence in vaccinated versus placebo recipients under ideal trial conditions. This number tells you what the vaccine can do. Vaccine effectiveness (VE_field) is different: it measures what the vaccine actually does in real-world populations, where vaccination is not randomized, conditions vary, strains drift, and immunity wanes. The gap between efficacy and effectiveness can be substantial and is the central focus of post-licensure vaccine surveillance.
The formula is the same regardless of study design: VE = 1 − RR (or 1 − OR when using case-control designs). If vaccinated individuals have 40% the disease risk of unvaccinated, VE = 1 − 0.40 = 60%. In a cohort study, you follow vaccinated and unvaccinated individuals and compare incidence rates — giving you a relative risk directly. In a case-control study, you compare vaccination status among cases and controls, yielding an odds ratio that approximates relative risk when disease is rare. Both designs require careful attention to confounding: vaccination status in real populations is not random. The healthy vaccinee bias — where healthier, more health-conscious people are more likely to get vaccinated — inflates VE estimates. Conversely, the frailty bias — where high-risk individuals are preferentially targeted for vaccination — deflates estimates. Uncontrolled confounders can make a marginally effective vaccine look excellent or an effective vaccine look useless.
The test-negative design is an elegant solution developed originally for influenza VE studies. Cases are patients who present to healthcare with flu-like illness and test positive for influenza; controls are patients with the same presentation who test negative. Because both groups sought care for similar symptoms, care-seeking behavior (a major confounder) is balanced between them. Vaccination status is then compared. The test-negative design removes the healthy-vaccinee bias almost entirely and is now the dominant design for rapid seasonal influenza effectiveness evaluation, requiring only routine surveillance data and no separate enrollment.
Waning immunity and strain mismatch are the two forces that make VE a moving target rather than a fixed property. Effectiveness against influenza declines measurably within a single season as vaccine-induced antibody titers fall and circulating strains evolve away from vaccine strains. For COVID-19, early VE estimates against severe disease exceeded 90% and fell substantially over 6–12 months. Time-stratified VE analysis — estimating effectiveness in strata defined by time since vaccination — captures this waning and informs booster timing decisions. Understanding that VE is not a single number but a function of pathogen, population, time, and endpoint (infection vs. symptomatic disease vs. hospitalization vs. death) is the key conceptual advance that separates sophisticated vaccine surveillance from naive headline-reading.